In summary, we discovered that activated platelets could remotely modulate ET-1 and VEGFA levels in vascular endothelial cells through the release of miR-200a-3p-containing PMVs via targeting MAPK14, which provides a potential miRNA-based therapeutic strategy for atherosclerosis related diseases. The gene discussed is VEGFA; the disease is atherosclerosis.